Get started

Financials · TRAW

Traws Pharma Inc. (TRAW) financials

For fiscal 2025 (ended Dec 31, 2025), Traws Pharma Inc. reported $2.79M of revenue and $9.17M of net income.

Revenue, FY2025
$2.79M
Revenue growth, YoY
+1134.5%
Net income, FY2025
$9.17M
Net margin
328.7%
Free cash flow, FY2025
-$20.77M
EPS, diluted, FY2025
$0.82
Cash
$5.02M
P/E
0.41
P/S
1.33
Market cap
$3.7M
Annual revenue$2.79M
FY2016FY2025
Annual net income$9.17M
FY2016FY2025
Annual free cash flow-$20.77M
FY2019FY2025

TRAW revenue and earnings growth

TRAW revenueQ4 2025$0

Quarter YoY
-100.0%
FY YoY
12x
5Y CAGR
+64.6%
10Y CAGR
-13.2%

TRAW revenue was $0 in fiscal Q4 2025 (ended Dec 31, 2025), down 100.0% from a year earlier. For the full fiscal 2025 it was $2.79M, up about 12-fold from fiscal 2024. Compound annual growth was +64.6% over 5 years and -13.2% over 10 years. It rose in 3 of the last 10 fiscal years.

TRAW net incomeQ2 2026-$3.05M

TRAW net income was -$3.05M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$915.0K a year earlier. For the full fiscal 2025 it was $9.17M, compared with -$166.52M in fiscal 2024. Fiscal 2025 is the highest of the 15 fiscal years on file.

TRAW EPSQ2 2026-$0.16

TRAW diluted EPS was -$0.16 in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was $0.82.

TRAW free cash flowQ4 2025-$2.76M

TRAW free cash flow was -$2.76M in fiscal Q4 2025 (ended Dec 31, 2025), compared with -$4.04M a year earlier. For the full fiscal 2025 it was -$20.77M, compared with -$33.44M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue$2.79M$226.0K$226.0K$226.0K$226.0K$231.0K$2.18M$1.23M$787.0K$5.55M
Research and development$12.14M$12.85M$11.43M$11.41M$7.30M$16.90M$15.54M$16.92M$19.12M$20.07M
Selling, general and admin$8.52M$12.29M$9.09M$8.45M$9.43M$8.33M$8.35M$7.59M$7.41M$9.18M
Operating income-$17.88M-$142.37M-$20.30M-$19.63M-$16.50M-$24.99M-$21.70M-$23.28M-$25.74M-$23.70M
Pre-tax income$9.17M-$166.53M-$18.95M-$18.96M-$16.16M-$25.15M-$21.49M-$20.53M-$24.08M-$19.65M
Income tax-----$4.0K$10.0K-$124.0K$13.0K$14.0K
Net income$9.17M-$166.52M-$18.95M-$18.96M-$16.16M-$25.16M-$21.50M-$20.57M-$24.09M-$19.67M
EPS, basic$0.83-$35.21-$22.57-$0.91-$0.96-$2.17-$22.35-$74.85-$602.25-$999.00
EPS, diluted$0.82-$35.21-$22.57-$0.91-$0.96-$2.17-$22.35-$74.85-$602.25-$999.00
Diluted shares8.4M1.6M839,55420.9M16.8M11.6M958,965.067274,938.240,001.46719,673.951

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Cash and equivalents$3.82M$21.34M$20.82M$38.76M$55.07M$19.02M$22.73M$16.97M$4.02M$21.45M
Receivables$3.79M$1.76M$18.0K$29.0K$28.0K$37.0K$98.0K$35.0K$59.0K$31.0K
Current assets$7.98M$24.95M$22.66M$39.35M$55.43M$19.78M$23.47M$17.77M$4.90M$23.07M
Total assets$10.62M$24.96M$22.68M$39.37M$55.48M$19.99M$23.67M$17.92M$4.98M$23.23M
Current liabilities$11.15M$11.53M$9.22M$8.05M$6.12M$10.02M$8.29M$8.44M$9.98M$10.16M
Total liabilities$11.25M$56.59M$12.01M$11.06M$9.36M$13.81M$12.10M$12.54M$15.84M$18.11M
Shareholders' equity-$629.0K-$31.63M$10.67M$28.31M$46.12M$6.17M$11.57M$5.39M-$10.86M$5.13M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Operating cash flow-$18.18M-$29.79M-$17.93M-$16.29M-$19.49M-$23.07M-$20.83M-$22.70M-$23.82M-$15.81M
Capital expenditures$2.58M$3.65M$14.0K--$15.0K$55.0K---
Free cash flow-$20.77M-$33.44M-$17.95M---$23.09M-$20.89M---
Investing cash flow-$2.58M-$3.65M-$14.0K---$15.0K-$55.0K---
Financing cash flow$3.20M$33.98M--$55.56M$19.36M$26.65M$35.66M$6.36M$17.42M
Stock-based compensation$728.0K$1.39M$1.30M$1.17M$576.0K$369.0K$1.05M$1.15M$1.71M$3.93M
Depreciation and amortization$61.0K$12.0K$16.0K$14.0K$14.0K$13.0K$14.0K$55.0K$88.0K$96.0K

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue growth, YoY1134.5%0.0%0.0%0.0%-2.2%-89.4%77.8%56.0%-85.8%-51.6%
Operating margin-640.7%-62997.3%-8981.4%-8684.5%-7299.1%-10819.5%-994.0%-1895.9%-3270.3%-427.4%
Net margin328.7%-73682.7%-8384.1%-8391.2%-7151.8%-10890.5%-985.0%-1675.3%-3061.2%-354.6%
Free cash flow margin-744.4%-14796.5%-7940.7%---9995.7%-956.8%---
Return on equity---177.5%-67.0%-35.0%-407.4%-185.8%-381.9%--383.6%
Return on assets86.4%-667.1%-83.5%-48.2%-29.1%-125.9%-90.8%-114.8%-483.9%-84.7%
Current ratio0.722.162.464.899.061.972.832.110.492.27

Source: XBRL data Traws Pharma Inc. files with the SEC, latest filing dated Aug 14, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures and share counts are restated for stock splits the filings show: 1-for-10, first reported Aug 15, 2016; 1-for-15, first reported Nov 14, 2018; 1-for-15, first reported Aug 16, 2021.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

TRAW peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
TRAW$2.79M+1134.5%$9.17M328.7%$3.7M
LLY$86.46B+45.5%$27.58B31.9%$1.33T
JNJ$99.33B+7.8%$16.09B16.2%$679.13B
ABBV$66.01B+10.7%$10.34B15.7%$518.44B
MRK$67.38B+4.9%$2.45B3.6%$366.73B
NVS$54.53B+8.4%$13.98B25.6%$312.35B
AZN$58.74B+8.6%$10.22B17.4%$293.69B
ABT$48.23B+10.0%$4.70B9.7%$191.40B
NVODKK 309.06B+6.4%DKK 102.43B33.1%$183.23B

TRAW FAQ

8 questions
  • What is TRAW revenue?
    Traws Pharma Inc. (TRAW) reported $2.79M of revenue for fiscal 2025 (ended Dec 31, 2025). That is up 1134.5% from the year before.
  • Is TRAW profitable?
    Yes. Traws Pharma Inc. earned $9.17M in net income for fiscal 2025 (ended Dec 31, 2025), a net margin of 328.7%.
  • How much cash and debt does TRAW have?
    Traws Pharma Inc. reported $5.02M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • How fast is TRAW revenue growing?
    Traws Pharma Inc.'s revenue changed 12x in fiscal 2025, to $2.79M. Its compound annual growth rate was +64.6% over 5 years and -13.2% over 10 years.
  • What is TRAW free cash flow?
    Traws Pharma Inc. generated -$20.77M of free cash flow for fiscal 2025 (ended Dec 31, 2025), which is operating cash flow of -$18.18M less capital expenditures.
  • What is TRAW earnings per share?
    Diluted earnings per share were $0.82 for fiscal 2025 (ended Dec 31, 2025), from SEC filings, restated for any stock split those filings show.
  • When did TRAW last report financial results?
    The latest statements here come from Traws Pharma Inc.'s 10-Q filed on Aug 14, 2026, covering the period ended Jun 30, 2026.
  • Where does this TRAW financial data come from?
    Quantisnow builds these statements from the structured XBRL data Traws Pharma Inc. files with the SEC. It is provided for information only and is not investment advice.